Stock Price
181.75
Daily Change
-0.60%
Yearly
57.74%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Adma Biologics 1.38 0.02 1.47% -37.84%
Adamas Pharmaceuticals 8.22 0.06 0.74% 91.16%
Agenus 3.32 0.09 2.79% 1.53%
AstraZeneca 8,284.00 61.00 0.74% 3.39%
Astrazeneca 55.13 0.38 0.68% 2.02%
BioCryst Pharmaceuticals 12.24 0.03 0.25% 68.60%
Dynavax Technologies 14.35 -0.10 -0.69% 209.27%
Geron 1.45 0.01 0.69% -15.70%
Genocea Biosciences 1.15 -0.02 -1.71% -46.01%
GlaxoSmithKline 1,591.80 16.00 1.02% 13.80%
Kindred Biosciences 9.24 -0.01 -0.11% 120.53%
MannKind 4.48 0.08 1.82% 58.87%
Merck & Co 73.21 0.93 1.29% -12.29%
Moderna Inc 283.40 1.05 0.37% 80.98%
Minerva Neurosciences 0.97 0.03 3.11% -63.63%
Novavax 181.75 -1.10 -0.60% 57.74%
Novartis 81.36 0.78 0.97% -11.19%
PDL BioPharma 2.47 0 0% -23.05%
Pfizer 51.40 -0.32 -0.62% 22.82%
Peregrine Pharmaceuticals 28.12 -0.38 -1.33% 163.79%
Cassava Sciences Inc. 49.98 2.33 4.89% 535.07%
Sanofi 84.60 -0.76 -0.89% 3.78%
Sarepta Therapeutics 86.02 0.69 0.81% -46.00%
TG Therapeutics 18.04 0.57 3.26% -39.10%

Indexes Price Day Year
NASDAQ 15787 100.07 0.64% 27.94%
US2000 2272 17.92 0.80% 19.43%

Novavax
Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases. The Company's product pipeline focuses on a range of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). The Company's lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. It is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. It is developing additional pre-clinical stage programs in a range of infectious diseases, including Middle East respiratory syndrome (MERS).